Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

1260-P: Verifying the Use of FIB4 and BARD Scores to Predict Advanced Fibrosis Using Transient Elastography in People with Type 2 Diabetes in a Tertiary Care Center in India

View through CrossRef
Background: There is a high prevalence of nonalcoholic fatty liver disease in people with type 2 diabetes. Liver biopsy is the gold standard for diagnosing advanced fibrosis but is usually not feasible in routine clinical practice. Transient elastography is accepted as a viable non-invasive alternative but is not universally available due to high cost. FIB4 and BARD scores are easy to perform in routine clinical practice and can guide for referral for transient elastography or liver biopsy. The aim of this study was to assess the utility of these simple scores (FIB4 and BARD) to exclude advanced fibrosis in people with type 2 diabetes. Material and Methods: A total of 133 consenting people were subjected to fibro scan. Serum markers (AST, ALT, Platelet count) were measured, and FIB 4 and BARD scores were calculated using standard equations. LSM (liver stiffness measurement) cut-off value of 11.4 was used to exclude advanced fibrosis. Results: Out of 133 people with diabetes in the study, 51.1% males and 48.9% were females, with a mean age of 50years, BMI 26.6, hba1c 8.7%, duration of diabetes 7.6yrs. The average LSM was 9.1, mean AST was 36 U/ml and ALT 38.5U/ml, platelet count was 208cubic mm. Mean FIB4 score was1.7 and BARD score was 3. 82.7% had a LSM value of <11.5 and 17.3% had a LSM value of>11.5%, neither BARD score nor FIB4 had significant correlation with liver stiffness measurement. Fib4 had a (Negative predictive value) NPV of 83.6% and BARD score had a NPV of 85.7% to exclude advanced fibrosis (>11.4) Conclusion: A FIB 4 score of less than 2.6 and BARD score of less than 2 have a high negative predictive value to exclude advanced fibrosis. Due to the high incidence of NAFLD in people with diabetes, these should be routinely used to exclude advanced fibrosis and the decision to referral for fibro scans and liver biopsy. Disclosure A. Tewari: None. J. Tewari: None. A. Maheshwari: None. V. Tewari: None. B. Tewari: None.
Title: 1260-P: Verifying the Use of FIB4 and BARD Scores to Predict Advanced Fibrosis Using Transient Elastography in People with Type 2 Diabetes in a Tertiary Care Center in India
Description:
Background: There is a high prevalence of nonalcoholic fatty liver disease in people with type 2 diabetes.
Liver biopsy is the gold standard for diagnosing advanced fibrosis but is usually not feasible in routine clinical practice.
Transient elastography is accepted as a viable non-invasive alternative but is not universally available due to high cost.
FIB4 and BARD scores are easy to perform in routine clinical practice and can guide for referral for transient elastography or liver biopsy.
The aim of this study was to assess the utility of these simple scores (FIB4 and BARD) to exclude advanced fibrosis in people with type 2 diabetes.
Material and Methods: A total of 133 consenting people were subjected to fibro scan.
Serum markers (AST, ALT, Platelet count) were measured, and FIB 4 and BARD scores were calculated using standard equations.
LSM (liver stiffness measurement) cut-off value of 11.
4 was used to exclude advanced fibrosis.
Results: Out of 133 people with diabetes in the study, 51.
1% males and 48.
9% were females, with a mean age of 50years, BMI 26.
6, hba1c 8.
7%, duration of diabetes 7.
6yrs.
The average LSM was 9.
1, mean AST was 36 U/ml and ALT 38.
5U/ml, platelet count was 208cubic mm.
Mean FIB4 score was1.
7 and BARD score was 3.
82.
7% had a LSM value of <11.
5 and 17.
3% had a LSM value of>11.
5%, neither BARD score nor FIB4 had significant correlation with liver stiffness measurement.
Fib4 had a (Negative predictive value) NPV of 83.
6% and BARD score had a NPV of 85.
7% to exclude advanced fibrosis (>11.
4) Conclusion: A FIB 4 score of less than 2.
6 and BARD score of less than 2 have a high negative predictive value to exclude advanced fibrosis.
Due to the high incidence of NAFLD in people with diabetes, these should be routinely used to exclude advanced fibrosis and the decision to referral for fibro scans and liver biopsy.
Disclosure A.
Tewari: None.
J.
Tewari: None.
A.
Maheshwari: None.
V.
Tewari: None.
B.
Tewari: None.

Related Results

Advancements in Elastography for Evaluating Fibrosis in Renal Transplants: Current Perspectives
Advancements in Elastography for Evaluating Fibrosis in Renal Transplants: Current Perspectives
Renal fibrosis is a leading cause of chronic allograft nephropathy. While renal biopsy remains the gold standard for diagnosing fibrosis, it is an invasive procedure with potential...
Evaluating the effect of methotrexate on the rate of renal fibrosis by elastography and fibrosis-related gene expression
Evaluating the effect of methotrexate on the rate of renal fibrosis by elastography and fibrosis-related gene expression
Methotrexate is mainly used to treat diseases such as rheumatoid arthritis (RA), but its potential for nephrotoxicity has always been a significant concern on the use of this medic...
Diabetes Awareness Among High School Students in Qatar
Diabetes Awareness Among High School Students in Qatar
Diabetes is a disease that occurs when there is an abundance of glucose in the blood stream and the body cannot produce enough insulin in the pancreas to transfer the sugar from th...
From liver biopsy to non-invasive markers in evaluating fibrosis in chronic liver disease
From liver biopsy to non-invasive markers in evaluating fibrosis in chronic liver disease
Chronic liver disease is a late stage of progressive hepatic fibrosis. It consists of functional and structural disruptions in most chronic liver diseases. An accurate diagnosis al...

Back to Top